Login to Your Account

Medicinova Gets the Green Light for MS Trial

By Catherine Shaffer
Staff Writer

Friday, July 19, 2013
Medicinova Inc. received funding and regulatory approval for a Phase IIb trial of its MS candidate, ibudilast. The project is funded by a $11.3 million grant from the National Institutes of Health for a cooperative effort by the NeuroNEXT clinical trial network.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription